EUVIMEDEUVIMED entdecken
Open Access

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy

Elizabeth S Duke iD, Diana Bradford, Arup K Sinha, Pallavi S Mishra-Kalyani, Catherine C Lerro, Donna Rivera iD, Emily Wearne, Claudia P Miller, John Leighton, Hairat Sabit, Hong Zhao, Ashley Lane und 6 weitere

Journal of Clinical Oncology · 2024-09 · 42 (25) · 3047-3057

DOI: 10.1200/jco.24.00546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024-09. Verfasst von Elizabeth S Duke und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Hauptthemen laut MEDLINE: Neuroblastoma, United States Food and Drug Administration, Drug Approval, Eflornithine. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On December 13, 2023, the US Food and Drug Administration (FDA) approved eflornithine (IWILFIN, US WorldMeds) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. The approval was based on an externally controlled trial (ECT) consisting of a single-arm trial, study 3(b), compared with an external control (EC) derived from a National Cancer Institute/Children's Oncology Group–sponsored clinical trial (Study ANBL0032) and supported by confirmatory evidence. In the protocol-specified primary analysis, the event-free survival hazard ratio (HR) was 0.48 (95% CI, 0.27 to 0.85) and overall survival HR was 0.32 (95% CI, 0.15 to 0.70). The most common adverse reactions (≥5%) were hearing loss, otitis media, pyrexia, pneumonia, and diarrhea. Notably, this is the first oncology drug approval which relies on an ECT as the primary clinical data to support substantial evidence of effectiveness. This was made possible by a distinctly high-quality, comparable EC data set with consistent treatment effect estimations demonstrated in multiple sensitivity and supportive analyses. Eflornithine's manageable safety profile and strong nonclinical and mechanistic data provided further support for the approval, and the evidentiary package was evaluated in the context of high unmet need in a rare, life-threatening cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaUnited States Food and Drug AdministrationDrug ApprovalEflornithineHumansUnited StatesChild, PreschoolMaleFemaleChildCombined Modality TherapyInfantAdolescentAdult

Substanzen

Eflornithine

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
  • Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD.

ORCID-Profile: Elizabeth S Duke, Donna Rivera, Richard Pazdur, Harpreet Singh

Förderung

  • Intramural FDA HHS

Zitieren

APA

Duke, E. S., Bradford, D., Sinha, A. K., Mishra-Kalyani, P. S., Lerro, C. C., Rivera, D., Wearne, E., Miller, C. P., Leighton, J., Sabit, H., Zhao, H., Lane, A., Scepura, B., Pazdur, R., Singh, H., Kluetz, P. G., Donoghue, M., & Drezner, N. (2024). US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy. Journal of Clinical Oncology, 42(25), 3047-3057. https://doi.org/10.1200/jco.24.00546

Vancouver

Duke ES, Bradford D, Sinha AK, Mishra-Kalyani PS, Lerro CC, Rivera D, et al. US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy. Journal of Clinical Oncology. 2024;42(25):3047-3057. doi:10.1200/jco.24.00546

BibTeX
@article{Duke2024,
  author = {Duke, Elizabeth S and Bradford, Diana and Sinha, Arup K and Mishra-Kalyani, Pallavi S and Lerro, Catherine C and Rivera, Donna and Wearne, Emily and Miller, Claudia P and Leighton, John and Sabit, Hairat and Zhao, Hong and Lane, Ashley and Scepura, Barbara and Pazdur, Richard and Singh, Harpreet and Kluetz, Paul G and Donoghue, Martha and Drezner, Nicole},
  title = {US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {25},
  pages = {3047--3057},
  doi = {10.1200/jco.24.00546}
}
Kostenlos starten →